Chronic Myeloid Leukemia Market

 Market Overview:

The 7 major chronic myeloid leukemia markets reached a value of US$ 5.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.5 Billion by 2034, exhibiting a growth rate (CAGR) of 4.03% during 2024-2034.

The chronic myeloid leukemia market has been comprehensively analyzed in IMARC's new report titled "Chronic Myeloid Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic myeloid leukemia (CML) refers to a form of tumor that affects the bone marrow and blood. It is mainly characterized by the uncontrolled growth of immature white blood cells (myeloid cells) in the bone marrow. The illness typically progresses slowly, and in the early phases, patients may not experience any symptoms. As the disease advances, some common indications may include fatigue, weight loss, abdominal swelling or discomfort, anemia, an enlarged spleen, reduced ability to exercise, easy bleeding or bruising, shortness of breath, etc. Individuals suffering from CML may also experience fever, pain in the bones, itching, a feeling of fullness, excessive sweating at night, etc. The diagnosis of this ailment involves a combination of medical history assessment, physical examination, and various laboratory tests. During a physical investigation, the medical practitioner will initially check for any signs of enlarged organs. A cytogenetic analysis is also recommended to identify the presence of abnormal chromosomes in the blood or bone marrow cells. Numerous blood workups, like a complete blood count and peripheral blood smear tests, are utilized to confirm a diagnosis among patients.

The increasing incidence of chromosomal abnormalities on account of genetic mutations, which promote the overgrowth of white blood cells, is primarily driving the chronic myeloid leukemia market. Additionally, the expanding geriatric population, who are more susceptible to age-related decline in the immune system that affects the body's ability to prevent the development of cancerous cells, is also propelling the market growth. Besides this, the emerging popularity of tyrosine kinase inhibitors, such as imatinib, dasatinib, nilotinib, etc., which work by blocking the action of specific faulty proteins in the body to treat tumors, is acting as another significant growth-inducing factor. Furthermore, the inflating adoption of immunotherapy, like interferon-alpha, for regulating the immune response and suppressing the spread of leukemia cells is also creating a positive outlook for the market. Apart from this, the escalating application of stem cell transplants that involve the replacement of diseased bone marrow with healthy stem cells in patients who have not responded to other pharmacological treatments is expected to drive the chronic myeloid leukemia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chronic myeloid leukemia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chronic myeloid leukemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic myeloid leukemia market in any manner.

Recent Developments:

• In July 2024, Novartis reported that Scemblix (asciminib) was awarded Priority Review status by the U.S. Food and Drug Administration (FDA) for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).
• In April 2024, Enliven Therapeutics reported positive proof of concept data from the Phase 1 clinical trial testing ELVN-001 in patients with chronic myeloid leukemia who are relapsed, resistant, or intolerant to existing tyrosine kinase inhibitors.
• In January 2024, Ascentage Pharma announced that olverembatinib had been included in the updated guidelines from the National Comprehensive Cancer Network (NCCN) for the therapy of chronic myeloid leukemia.

Key Highlights:

• Chronic myeloid leukemia is a clonal hematopoietic stem cell disease that accounts for roughly 30% of all adult leukemias.
• The incidence of chronic myeloid leukemia increases with age and is rare in children under the age of 14 (0.7/million children per year).
• Chronic myeloid leukemia is more common in males than in females, with a male/female ratio of 1.2–1.7.
• According to the American Cancer Society, there will be approximately 9,280 new cases of chronic myeloid leukemia in the United States in 2024 (5,330 men and 3,950 women).
• Regardless of age, over 90% of persons with chronic myeloid leukemia survive at least five years after being diagnosed.

Drugs:

BOSULIF is a prescription medication that treats adults and children aged one year and up with chronic phase Ph+ CML who are newly diagnosed or who no longer benefit from or did not tolerate previous treatment. BOSULIF is a tyrosine kinase inhibitor, which can inhibit BCR-ABL function, thereby reducing the development of leukemia cells.

ELVN-001 is a potent, highly selective small molecule kinase inhibitor that targets the BCR-ABL gene fusion, the oncogenic driver in chronic myeloid leukemia. ELVN-001, a highly selective active site inhibitor, has a mode of action that complements allosteric BCR::ABL1 inhibitors, which may play an increasing role in the standard of treatment.

Vodobatinib is a medication under investigation for chronic myeloid leukemia. Vodobatinib is an orally active, third-generation tyrosine kinase inhibitor that is effective against the majority of BCR-ABL1 point mutations. Vodobatinib stimulates autophagy, causing quickly dividing cells to die.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic myeloid leukemia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic myeloid leukemia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic myeloid leukemia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chronic myeloid leukemia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the chronic myeloid leukemia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the chronic myeloid leukemia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of chronic myeloid leukemia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic myeloid leukemia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic myeloid leukemia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with chronic myeloid leukemia across the seven major markets?
• What is the size of the chronic myeloid leukemia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of chronic myeloid leukemia?
• What will be the growth rate of patients across the seven major markets?
   

Chronic Myeloid Leukemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chronic myeloid leukemia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic myeloid leukemia market?
• What are the key regulatory events related to the chronic myeloid leukemia market?
• What is the structure of clinical trial landscape by status related to the chronic myeloid leukemia market?
• What is the structure of clinical trial landscape by phase related to the chronic myeloid leukemia market?
• What is the structure of clinical trial landscape by route of administration related to the chronic myeloid leukemia market?